General therapy of persons with diabetic foot syndrome;Allgemeine therapie der menschen mit diabetischem fusssyndrom (DFS)

Internist

Volumn 40, Issue 10, 1999, Pages 1018-1023

  Landgraf, R ^a   Hierl, F X ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMITRIPTYLINE; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; CAPSAICIN; CARBAMAZEPINE; CEPHALOSPORIN; CILASTATIN PLUS IMIPENEM; CLINDAMYCIN; DESIPRAMINE; IMIPRAMINE; LIDOCAINE; METRONIDAZOLE; MEXILETINE; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULTAMICILLIN; TEICOPLANIN; UNINDEXED DRUG; VANCOMYCIN;

ALCOHOL ABSTINENCE; ANTIBIOTIC THERAPY; BLOOD PRESSURE REGULATION; DIABETES MELLITUS; DIABETIC FOOT; DIABETIC NEUROPATHY; DYSLIPOPROTEINEMIA; INFECTION; ORAL DRUG ADMINISTRATION; PERIPHERAL OCCLUSIVE ARTERY DISEASE; REVIEW; RISK FACTOR; SMOKING CESSATION; THROMBOCYTE AGGREGATION INHIBITION; WEIGHT REDUCTION;

COMBINED MODALITY THERAPY; DIABETIC ANGIOPATHIES; DIABETIC FOOT; DIABETIC NEUROPATHIES; HUMANS; PATIENT CARE TEAM; RISK FACTORS;

EID: 0032850029     PISSN: 00209554     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001080050432     Document Type: Review

References (56)

1. Estacio RO, Schrier RW (1998) Antihypertensive therapy in type 2 diabetes: implications of the appropriate blood pressure control in diabetes (ABCD) trial. Am J Cardiol 12:9R-14R
2. Antiplatelet Trialist Collaboration (1994) Collaborative overview of randomised trials of antiplatelet therapy. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Brit Med J 308:81-106
3. Apelqvist J, Agardh C-D (1992) The association between clinical factors and outcome of diabetic foot ulcers. Diabetes Res Clin Pract 18:43-53
4. Apelqvist J, Larsson J, Agardh C-D (1990) The importance of peripheral pulses, peripheral oedema and local pain in the outcome of diabetic foot ulcers. Diabetic Med 7:590-594
5. Apelqvist J, Larsson J, Agardh C-D (1992) Medical risk factors in diabetic patients with foot ulcers and severe peripheral vascular disease and their influence on outcome. J Diabetes Compl 6:167-174
6. Armstrong DG, Lavery LA, Harkless B (1998) Validation of a diabetic wound classification system. The contribution of depth, infection, and ischemia to risk of amputation. Diabetes Care 21:855-859
7. Bakker K, Dooren J (1994) A specialised outpatient foot clinic for diabetic patients decreases the number of amputations and is cost saving. Ned Tijdschr Geneeskd 11:565-569
8. Boyko EJ, Ahroni JH, Smith DG, Davignon D (1996) Increased mortality with diabetic foot ulcer. Diabetic Med 13:967-72
9. CAPRIE Steering Committe (1996) A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348:1329-1339
10. Caputo GM, Cavanagh PR, Ulbrecht JS, Gibbons GW, Karchmer AW (1994) Assessment and management of foot disease in patients with diabetes. N Engl J Med 331:854-860
11. Chantelau E (1995) Amputation? Nein danke! Kirchheim Verlag, Mainz
12. Chantelau E, Tanudjaja T, Altenhöfer F, Ersanti Z, Iacigova S, Metzger C (1996) Antibiotic treatment for uncomplicated neuropathic forefoot ulcer in diabetes: a controlled trial. Diabetic Med 13:156-159
13. Colwell J A (1992) Antiplatelet drug and prevention of macrovascular disease in diabetes mellitus. Metabolism 41:7-10
14. Consensus Document on Chronic Critical Leg Ischemia (1991) Circulation 84:3-26
15. Da Silva AF, Desgranges P, Holdsworth J et al. (1996) The management and outcome of critical limb ischaemia in diabetic patients: results of a national survey. Diabetic Med 13:135-140
16. DCCT Research Group (1993) The effect of intensive treatment of diabetes on the developement and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986
17. Del Aguila M A, Reiber GE, Koepsell TD (1994) How does provider and patient awareness of high-risk status for lower-extremity amputation influence foot-care practice? Diabetes Care 9:1050-1054
18. Edelson GV (1998) Systematic and nutritional considerations in diabetic wound healing. Clin Podiatr Med Surg 1:41-48
19. Edmonds ME, van Acker K, Foster AVM (1996) Education and the diabetic foot. Diabetic Med 13 [Suppl 1]:61-64
20. Faglia E, Favales F, Aldeghi A et al. (1998) Change in major amputation rate in a center dedicated to diabetic foot care during the 1980s: prognostic determinants for major amputation. J Diabetes Compl 2:96-102
21. Goldstein E, Citron D, Nesbit C (1996) Diabetic foot infections. Bacteriology and activity of 10 oral antimicrobial agents against bacteria isolated from consecutive cases. Diabetes Care 19:638-641
22. Grayson M (1995) Diabetic foot infections. Antimicrobial therapy. Inf Dis Clin North Am 143-161
23. Grundy AM (1997) Small LDL, atherogenic dyslipidaemia, and the metabolic syndrome. Circulation 95:1-4
24. Hasson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S, Menard J, Rahn KH, Wedel H, Westerling S for the HOT Study Group (1998) Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 351:1755-1762
25. Haslbeck M (1998) Klinik der diabetischen Neuropathien. In: Federlin K (wiss. Leitung) Pathophysiologie diabetischer Folgeerkrankungen. Aktuelles Wissen Hoechst, Hoechst AG, S 108-121
26. Hepp WW (1996) Der diabetische Fuß. Blackwell, Oxford, S 1-195
27. Hoes AW, Grobbee DE, Lubsen J (1995) Does drug treatment improve survival? Reconceiling the trials in mild-to-moderate hypertension. J Hypertens 13:805-811
28. International Working Group on the diabetic foot (1999) International Consensus on the diabetic foot. Third international symposium, May 1999, Noordwijkerhout,The Netherlands
29. Kannel WB, Gordon T, Wolf PA, McNamara P (1982) Haemoglobin and risk of cerebral infarction. The Framingham Study. Stroke 3:490-493
30. Laakso M (1995) Epidemiology of diabetic dyslipidaemia. Diabet Rev 3:408-422
31. Lam KSL, Cheng IKP Janis ED, Pang RWC (1995) Cholesterol lowering therapy may retard the progression of diabetic nephropathy. Diabetologia 38:604-609
32. Landgraf R (1996) Impact of pancreas transplantation on diabetic secondary complications and quality of life. Diabetologia 39:1415-1424
33. Larsen K, Holstein P, Deckert T (1989) Limb salvage in diabetics with foot ulcers. Prosthet Orthot Int 2:100-103
34. Lipsky BA, Baker PD, Landon GC, Fernau R (1997) Antibiotic treatment for diabetic foot infections: comparison of two parenteral-to-oral regimens. Clin Infect Dis 4:643-648
35. LoGerfo FW, Gibbons GW, Pomposelli FB Jr. et al. (1992) Trends in the care of the diabetic foot. Expanded role of arterial reconstruction. Arch Surg 5:617-620
36. Luft D (1996) Therapeutische Strategien bei der diabetischen Neuropathie. Med Klin 91:295-301
37. McIntyre Bridges Jr. R, Deitch EA (1994) Diabetic foot infections. Pathophysiology and treatment. Surg Clinics of North America 3:537
38. Mogensen CE, Standl E (1989) Prevention and treatment of diabetic late complications. De Gruyter, Berlin
39. Mustard JF, Packham MA (1984) Platelets and diabetes mellitus. N Engl J Med 311:133-135
40. Oughton J, Barnes AJ, Kohner EM (1981) Diabetes mellitus: its effect on the flow properties of blood. In: Standl E, Mehnert (eds) Pathogenetic concept of diabetic microangiopathy. Thieme Verlag, Stuttgart
41. Panzram G (1987) Mortality and survival in type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 30:123-131
42. Patrono C, Davi G (1993) Antiplatelet agents in the prevention of diabetic vascular complications. Diabet Metab Rev 9:177-188
43. Piaggesi A, Schipani E, Campi F et al. (1998) Conservative surgical approach versus non-surgical management for diabetic neuropathic foot ulcer: a randomised trial. Diabetic Med 5:412-417
44. Pyörälä K, Petersen TR, Kjekshus J, Faergmann O, Olsson AG, Thorgeirsson G (1997) Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4 S). Diabetes Care 20:614-620
45. Reeves WG, Wilson RM (1992) Infection, immunity, and diabetes. In: Alberti KGMM, DeFonzo RA, Kleen H et al. (eds) International Textbook of Diabetes mellitus. West Sussex, John Wiley and Sons, pp 63-98
46. Reike H (Hrsg) (1999) Das diabetische Fußsyndrom. De Gruyter, Berlin
47. Ronnemaa T, Hamalainen H, Toikka T, Liukkonen l (1997) Evaluation of the impact of podiatrist care in the primary prevention of foot problems in the diabetic subjects. Diabetes Care 12:1833-1837
48. Roth FJ, Koppers B, Rieser R, Scheffler A (1991) Angioplastie in der unteren Extremität bei Diabetes mellitus. In: Schütz RM, Bruch HP (Hrsg) Der diabetische Patient. 12. Norddeutsche Angiologietage
49. Stegmayr BG, Lithner F (1987) Tobacco and end stage diabetic nephropathy. Brit Med J 295:581-582
50. Scandinavian Simvastatin Survival Study Group (1995) Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4 S). Lancet 345:1274-1275
51. Stiegler H, Standl B, Standl E, Hillebrand B (1995) Der diabetische Fuß: Die wesentliche Rolle spielt die Prävention. Dtsch Ärztebl 92:591-595
52. Stiegler H, Standl R, Standl E (1999) Hirnund extremitätenversorgende Arterien. In: Mehnert H, Standl E, Usadel K-H (Hrsg) Diabetologie in Klinik und Praxis. Thieme Verlag, Stuttgart S 384-406
53. Strian F, Haslbeck M, Standl E (1994) Behandlung schmerzhafter Diabetesneuropathien. Internist 35:32-40
54. UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853
55. UKPDS Group (1998) Tight blood-pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38). Brit Med J 317:703-713
56. Wayne K, Stadelmann MD, Alexander G, Digenis MD, Gordon R, Tobin MD (1998) Impediments to wound healing. Am J Surg 176 [Suppl 2a]: 39-47